During the last session, Akebia Therapeutics Inc. (NASDAQ:AKBA)’s traded shares were 2.7 million, with the beta value of the company hitting 0.77. At the end of the trading day, the stock’s price was $1.70, reflecting an intraday loss of -0.58% or -$0.01. The 52-week high for the AKBA share is $2.48, that puts it down -45.88 from that peak though still a striking 52.94% gain since the share price plummeted to a 52-week low of $0.80. The company’s market capitalization is $357.49M, and the average intraday trading volume over the past 10 days was 2.35 million shares, and the average trade volume was 1.68 million shares over the past three months.
Akebia Therapeutics Inc. (AKBA) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. AKBA has a Sell rating from 0 analyst(s) out of 4 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 4 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.06.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Akebia Therapeutics Inc. (NASDAQ:AKBA) trade information
Akebia Therapeutics Inc. (AKBA) registered a -0.58% downside in the last session and has traded in the green over the past 5 sessions. The stock plummet -0.58% in intraday trading to $1.70, hitting a weekly high. The stock’s 5-day price performance is 6.92%, and it has moved by 32.81% in 30 days. Based on these gigs, the overall price performance for the year is 100.99%. The short interest in Akebia Therapeutics Inc. (NASDAQ:AKBA) is 17.68 million shares and it means that shorts have 14.06 day(s) to cover.
The consensus price target of analysts on Wall Street is $6.5, which implies an increase of 73.85% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $6 and $7 respectively. As a result, AKBA is trading at a discount of -311.76% off the target high and -252.94% off the low.
Akebia Therapeutics Inc. (AKBA) estimates and forecasts
Statistics show that Akebia Therapeutics Inc. has outperformed its competitors in share price, compared to the industry in which it operates. Akebia Therapeutics Inc. (AKBA) shares have gone up 37.10% during the last six months, with a year-to-date growth rate more than the industry average at 32.14% against 17.50. In the rating firms’ projections, revenue will decrease -11.60% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 44.51M as predicted by 3 analyst(s). Meanwhile, a consensus of 3 analyst(s) estimates revenue growth to 51.22M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 42.05M and 56.2M respectively. In this case, analysts expect current quarter sales to grow by 5.90% and then drop by -8.90% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 35.46%. While earnings are projected to return 13.10% in 2024.
AKBA Dividends
Akebia Therapeutics Inc. is due to release its next quarterly earnings in November. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Akebia Therapeutics Inc. (NASDAQ:AKBA)’s Major holders
Akebia Therapeutics Inc. insiders own 2.17% of total outstanding shares while institutional holders control 26.86%, with the float percentage being 27.46%. BLACKROCK INC. is the largest shareholder of the company, while 130.0 institutions own stock in it. As of 2024-06-30, the company held over 11.64 million shares (or 5.6786% of all shares), a total value of $11.87 million in shares.
The next largest institutional holding, with 9.28 million shares, is of VANGUARD GROUP INC’s that is approximately 4.526% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $9.46 million.
